7. Secondary outcome ‐ condition‐specific outcomes.

Study	Measure	Outcome
Blalock 2010	Falls (self‐reported) in 12 months (ITT analysis)	≥ 1 fall: 53/93 vs 52/93
Bond 2007	Total score (/8) for reaching targets at 12 months (aspirin, lipid, BP, smoking, alcohol, physical activity, diet, BMI)	4.6 ± 1.2 vs 4.6 ± 1.1
Cohen 2011	Percentage achieving targets at 6 months (SBP < 130, LDL < 100, HbA1c < 7%)	16% (n = 50) vs 4.1% (n = 49)
Lee 2006	Systolic and diastolic blood pressure (mmHg) and LDL‐cholesterol (mg/dL) at 6 months post phase 1	SBP: 124.4 ± 14.0 vs 133.3 ± 21.5 DBP: 67.5 ± 9.9 vs 68.6 ± 10.5 LDL: 87.5 ± 24.2 vs 88.4 ± 21.0
Nascimento 2016	Fasting blood glucose and HbA1c at 6 months	FBG: 117.3 ± 26.8 vs 142.2 ± 32.9 HbA1C: 7.7 ± 0.8 vs 7.99 ± 0.67
Taylor 2003	Number of people reaching goal level at 12 months (BP ≤ 140/90, HbA1c ≤ 7.5%, INR 2 to 3, LDL)	BP: 22 (91.7%) vs 8 (27.6%) Diabetes: 13 (100%) vs 5 (26.7%) INR: 4 (100%) vs 1 (16.7%) LDL: 14 (77.8%) vs 1 (5.9%) (Note: calculated mean across all 4 measures: 92% vs 19%)
Williams 2012	Blood pressure, HbA1c, eGFR, and creatinine levels at 12 months (9 months post intervention)	SBP: mean (CI) ‐6.9 (‐13.8 to 0.02) vs ‐3.0 (‐8.4 to 2.4) HbA1c: med (IQR): 7 (7 to 9) vs 8 (7 to 9) eGFR: med (IQR): 48 (38 to 76) vs 46 (32 to 72) Creatinine: med (IQR): 117 (82 to 144) vs 108 (89 to 171)

Outcome results presented as intervention group vs usual care group unless otherwise stated and presented as mean ± SD unless otherwise stated.

BMI: body mass index.

BP: blood pressure.

DBP: diastolic blood pressure.

eGFR: estimated glomerular filtration rate.

FBG: fasting blood glucose.

HbA1c: glycosylated haemoglobin.

INR: international normalised ratio.

IQR: interquartile ratio.

ITT: intention‐to‐treat.

LDL: low‐density lipoprotein.

SBP: systolic blood pressure.